MA54512A - Dérivés de la quinoléine destinés à une utilisation dans le traitement ou la prévention du cancer - Google Patents

Dérivés de la quinoléine destinés à une utilisation dans le traitement ou la prévention du cancer

Info

Publication number
MA54512A
MA54512A MA054512A MA54512A MA54512A MA 54512 A MA54512 A MA 54512A MA 054512 A MA054512 A MA 054512A MA 54512 A MA54512 A MA 54512A MA 54512 A MA54512 A MA 54512A
Authority
MA
Morocco
Prior art keywords
cancer
prevention
treatment
quinoline derivatives
quinoline
Prior art date
Application number
MA054512A
Other languages
English (en)
Inventor
Hartmut Ehrlich
Philippe Pouletty
Didier Scherrer
Jamal Tazi
Original Assignee
Abivax
Centre Nat Rech Scient
Inst Curie
Univ Montpellier
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abivax, Centre Nat Rech Scient, Inst Curie, Univ Montpellier filed Critical Abivax
Publication of MA54512A publication Critical patent/MA54512A/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4709Non-condensed quinolines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/675Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38Nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
MA054512A 2018-12-20 2019-12-19 Dérivés de la quinoléine destinés à une utilisation dans le traitement ou la prévention du cancer MA54512A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP18306783.4A EP3669874A1 (fr) 2018-12-20 2018-12-20 Dérivés de la quinoline destinés à être utilisés dans le traitement ou la prévention du cancer

Publications (1)

Publication Number Publication Date
MA54512A true MA54512A (fr) 2021-10-27

Family

ID=65200518

Family Applications (1)

Application Number Title Priority Date Filing Date
MA054512A MA54512A (fr) 2018-12-20 2019-12-19 Dérivés de la quinoléine destinés à une utilisation dans le traitement ou la prévention du cancer

Country Status (11)

Country Link
US (1) US20220071985A1 (fr)
EP (2) EP3669874A1 (fr)
JP (1) JP7570641B2 (fr)
KR (2) KR20210136969A (fr)
CN (2) CN113543784A (fr)
AU (1) AU2019408244B2 (fr)
BR (1) BR112021012132A2 (fr)
IL (1) IL284124B2 (fr)
MA (1) MA54512A (fr)
MX (1) MX2021007178A (fr)
WO (1) WO2020127839A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023126951A1 (fr) * 2022-01-03 2023-07-06 Yeda Research And Development Co. Ltd. Inhibiteurs d'interactions protéine-protéine liées à l'autophagie
WO2024109936A1 (fr) * 2022-11-25 2024-05-30 江苏恒瑞医药股份有限公司 Forme cristalline de composé de quinoléine amine et son procédé de préparation
WO2025027388A1 (fr) 2023-08-01 2025-02-06 Abivax Obéfazimod pour le traitement de la rectocolite hémorragique
CN121532389A (zh) * 2023-08-30 2026-02-13 江苏正大丰海制药有限公司 用于调节微小rna-124活性的化合物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR201910781T4 (tr) 2009-06-12 2019-08-21 Abivax Kanser tedavisi için yararlı bileşikler.
EP2465502A1 (fr) 2010-12-15 2012-06-20 Société Splicos Composés utiles pour traiter le SIDA
EP2757161A1 (fr) 2013-01-17 2014-07-23 Splicos miRNA-124 comme biomarqueur de l'infection virale
CN103787992B (zh) * 2014-01-21 2016-04-20 华东理工大学 N,n-双取代苯并氮杂环-2-胺类化合物及其用途
EP2975034A1 (fr) 2014-07-17 2016-01-20 Abivax Dérivé de quinoléine pour le traitement de maladies inflammatoires et du sida
EP2974729A1 (fr) * 2014-07-17 2016-01-20 Abivax Dérivés de quinoléine utilisés dans le traitement de maladies inflammatoires
EP3059236A1 (fr) * 2015-02-23 2016-08-24 Abivax Nouveau dérivé de quinoléine pour utilisation dans le traitement et la prévention d'infections virales
JP6474334B2 (ja) * 2015-07-30 2019-02-27 株式会社キーエンス 画像検査装置、画像検査方法および画像検査プログラム
US10464903B2 (en) * 2016-03-18 2019-11-05 Ratiopharm Gmbh Process for preparing quinolin-2-yl-phenylamine derivatives and their salts

Also Published As

Publication number Publication date
IL284124A (en) 2021-08-31
IL284124B2 (en) 2025-07-01
US20220071985A1 (en) 2022-03-10
JP7570641B2 (ja) 2024-10-22
AU2019408244B2 (en) 2025-03-20
CA3122912A1 (fr) 2020-06-25
MX2021007178A (es) 2021-07-07
CN113543784A (zh) 2021-10-22
CN118986981A (zh) 2024-11-22
WO2020127839A1 (fr) 2020-06-25
KR20210136969A (ko) 2021-11-17
KR20250117703A (ko) 2025-08-05
EP3897639A1 (fr) 2021-10-27
AU2019408244A1 (en) 2021-07-08
IL284124B1 (en) 2025-03-01
JP2022513517A (ja) 2022-02-08
EP3669874A1 (fr) 2020-06-24
BR112021012132A2 (pt) 2021-09-08

Similar Documents

Publication Publication Date Title
EP3455205A4 (fr) Peptidomimétiques pour le traitement d'une infection à norovirus
EP3600281A4 (fr) Traitement d'association pour le traitement ou la prévention de tumeurs
EP3781564C0 (fr) Dérivés de pyridazine pour le traitement du cancer
MA49760A (fr) Mavacamten destiné à être utilisé dans le traitement de la cardiomyopathie hypertrophique
EP3533466A4 (fr) Composition pharmaceutique pour le traitement et/ou la prévention du cancer
MA43746A (fr) Dérivés de 2-cyanoisoindoline pour le traitement du cancer
MA45146A (fr) Dérivés de pyrazolopyridine pour le traitement du cancer
MA54512A (fr) Dérivés de la quinoléine destinés à une utilisation dans le traitement ou la prévention du cancer
MA44020B1 (fr) Composés antitumoraux
EP3405183A4 (fr) Dérivés d'adamatane pour le traitement d'une infection à filovirus
MA51139A (fr) Dérivés de 1-(pipéridinocarbonylméthyl)-2-oxopipérazine pour le traitement du cancer
EP3317274A4 (fr) Utilisation de composés de chloroquine et de clémizole pour le traitement d'états pathologiques inflammatoires et cancéreux
EP3419981A4 (fr) Polythérapies utilisées dans le traitement de l'amyotrophie spinale
EP3813870C0 (fr) Inhibiteur de ccr5 destiné à être utilisé dans le traitement du cancer
EP3805216A4 (fr) Composés pour le traitement ou la prévention de maladies hépatiques
EP3471722A4 (fr) Composés et méthodes pour la prévention et/ou le traitement du cancer
EP3313818A4 (fr) Procédés pour le traitement du sarcome de kaposi ou le lymphome induit par le kshv à l'aide de composés immunomodulateurs et utilisations de biomarqueurs
MA47111A (fr) Agents ciblant sirpgamma destinés à être utilisés dans le traitement du cancer
EP3632431A4 (fr) Agent de prévention ou de traitement de l'atrophie cérébrale
MA51613A (fr) Polythérapie pour le traitement ou la prévention du cancer
MA51821A (fr) Inhibiteurs de la thiorédoxine réductase à utiliser dans le traitement du cancer
EP3636261A4 (fr) Agent pour prévenir ou traiter une tauopathie
EP3632430A4 (fr) Agent de prévention ou de traitement de l'ataxie spinocérébelleuse
EP3533471A4 (fr) Composition pour le soulagement ou le traitement de la douleur
EP3400025A4 (fr) Utilisation de gaïacol pour la prévention et le traitement de glycogénoses